EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)

Silvia Masini iD, Monica Antoñanzas Basa, Antonio Calles iD, Ruth Alvarez Cabellos, Ibone De Elejoste Echebarria iD, Cristina Traseira Puchol iD, Mireia Martinez Kareaga iD, Luis Cabezon-Gutierrez iD, Maria Corina Escoin Perez, Yolanda Lage iD, Ester Garcia Lorenzo, Fatima Navarro und 22 weitere

Cancers · 13.11.2025 · 17 (22) · 3643

DOI: 10.3390/cancers17223643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.11.2025. Verfasst von Silvia Masini und 33 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital 12 de Octubre, 28041 Madrid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SEOM Research Grant for Lung Cancer Projects, TAKEDA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Anti–PD-1/PD-L1 blockers have revolutionized the treatment landscape of non–small cell lung cancer (NSCLC) lacking oncogene-addicted alterations, particularly in tumors with high PD-L1 expression (tumor proportion score [TPS] ≥ 50%). Cemiplimab is approved as first-line monotherapy in this setting. However, real-world data remain scarce. This study aimed to evaluate the efficacy and safety of single-agent cemiplimab in a multicenter Spanish cohort and compare outcomes with a historical pembrolizumab cohort.

Methods

Cemi-SPA is a retrospective multicenter study including 150 patients with advanced NSCLC and PD-L1 ≥ 50% treated with cemiplimab as first-line monotherapy across 21 Spanish centers. Clinical outcomes were analyzed and compared with a historical cohort of 144 patients treated with pembrolizumab. Propensity score matching (PSM) was performed to adjust for baseline differences.

Results

Median progression-free survival (PFS) and overall survival (OS) were 8.1 and 12.6 months, respectively. ECOG performance status ≥ 2 was independently associated with worse outcomes, whereas the development of immune-related adverse events correlated with improved PFS and OS. After PSM, no significant differences were observed between cemiplimab and pembrolizumab in terms of efficacy.

Conclusions

Cemiplimab demonstrated comparable real-world efficacy and safety to pembrolizumab in patients with advanced NSCLC and PD-L1 ≥ 50%. ECOG performance status emerged as the strongest prognostic factor, highlighting the importance of patient selection in routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

NSCLCPD-L1immunotherapy

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital 12 de Octubre, 28041 Madrid, Spain.
  • Medical Oncology Department, Humanitas University, 20072 Milan, Italy.
  • Medical Oncology Department, Hospital Clinico Universitario San Carlos, 28040 Madrid, Spain.
  • Medical Oncology Department, Hospital Gregorio Marañón, 28007 Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario de Toledo, 45007 Toledo, Spain.
  • Medical Oncology Department, Hospital Universitario Donostia, 20014 Donostia, Spain.

ORCID-Profile: Silvia Masini, Antonio Calles, Ibone De Elejoste Echebarria, Cristina Traseira Puchol, Mireia Martinez Kareaga, Luis Cabezon-Gutierrez, Yolanda Lage, Laura Masfarre Pinto, Silvia Sequero, Joaquín Mosquera Martinez, Ana López-Martín, Aitor Azkárate Martínez, Clara Lucia-Gozalvez, Melina Peressini, Javier Torres-Jimenez, Helena Bote, Javier Baena

Förderung

  • SEOM Research Grant for Lung Cancer Projects
  • TAKEDA

Zitieren

APA

Masini, S., Antoñanzas Basa, M., Calles, A., Cabellos, R. A., De Elejoste Echebarria, I., Traseira Puchol, C., Martinez Kareaga, M., Cabezon-Gutierrez, L., Escoin Perez, M. C., Lage, Y., Garcia Lorenzo, E., Navarro, F., Sereno, M., Falagán Martínez, S., García-Benito, C., Masfarre Pinto, L., Avila Andrade, C., Sequero, S., Mosquera Martinez, J., …, & Baena, J. (2025). Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study). Cancers, 17(22), 3643. https://doi.org/10.3390/cancers17223643

Vancouver

Masini S, Antoñanzas Basa M, Calles A, Cabellos RA, De Elejoste Echebarria I, Traseira Puchol C, et al. Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study). Cancers. 2025;17(22):3643. doi:10.3390/cancers17223643

BibTeX
@article{Masini2025,
  author = {Masini, Silvia and Antoñanzas Basa, Monica and Calles, Antonio and Cabellos, Ruth Alvarez and De Elejoste Echebarria, Ibone and Traseira Puchol, Cristina and Martinez Kareaga, Mireia and Cabezon-Gutierrez, Luis and Escoin Perez, Maria Corina and Lage, Yolanda and Garcia Lorenzo, Ester and Navarro, Fatima and Sereno, Maria and Falagán Martínez, Sandra and García-Benito, Carme and Masfarre Pinto, Laura and Avila Andrade, Claudio and Sequero, Silvia and Mosquera Martinez, Joaquín and López-Martín, Ana and Azkárate Martínez, Aitor and Martín-Soberón, Maria Cruz and Lucia-Gozalvez, Clara and Rubio, Judit and Tallafigo, Leopoldo and Garrido, Alberto and Peressini, Melina and Torres-Jimenez, Javier and Zurera, María and Bote, Helena and Ponce, Santiago and Paz-Ares, Luis and Zugazagoitia, Jon and Baena, Javier},
  title = {Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {22},
  pages = {3643},
  doi = {10.3390/cancers17223643}
}
Kostenlos starten →